What Challenges Exist in the Toxicological Assessment of TB Drugs?
One of the primary challenges is the inherent complexity of TB infection, which necessitates prolonged treatment duration. This increases the likelihood of long-term toxicity. Moreover, the co-administration of TB drugs with other medications, such as antiretrovirals in HIV co-infected patients, complicates the assessment of drug interactions and cumulative toxicity. Additionally, species differences in metabolism between animals and humans can make it difficult to extrapolate preclinical findings to clinical settings.
